Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway

American Journal of Respiratory and Critical Care Medicine

Volumn 167, Issue 2, 2003, Pages 199-204

  Flood Page, Patrick T ^a   Menzies Gow, Andrew N ^a   Kay, A Barry ^a   Robinson, Douglas S ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Anti interleukin 5; Asthma; Eosinophils

Indexed keywords

INTERLEUKIN 5 ANTIBODY; MAJOR BASIC PROTEIN; MEPOLIZUMAB;

ADULT; ARTICLE; ASTHMA; BONE MARROW; BRONCHUS HYPERREACTIVITY; BRONCHUS MUCOSA; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ASTHMA; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EOSINOPHILIA; EOSINOPHILS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; RESPIRATORY FUNCTION TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0037438409     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200208-789OC     Document Type: Article

References (28)

1. Dunnill MS. The pathology of asthma. In: Middleton E, Reed CE, Ellis EF, editors. Allergy: Principles and Practice. St. Louis, MO: CV Mosby, 1978. p. 678.
2. Filley WV, Holley KE, Kephart GM, Gleich GJ. Identification by immunofluorescence of eosinophil granule major basic protein in lung tissue of patients with bronchial asthma. Lancet 1982;2:11-16.
3. Bosquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033-1039.
4. Clutterbuck EJ, Hirst EM. Sanderson CJ. Human interleukin-5 regulates the production of eosinophils in human bone marrow cultures: Comparison and interaction with IL-1, IL-3, IL-6 and GM-CSF. Blood 1989:73:1504-1512.
5. Yamaguchi Y, Duda T, Suda J, Eguchi M, Miura Y, Harada N, Tominaga A, Takatsu K. Purified interleukin-5 supports the terminal differentiation and proliferation of murine eosinophil precursors. J Exp Med 1988;167:43-56.
6. Tavernier J, Van de Heyden J, Verhee A, Brussell G, Van Ostade X, Vandekerckhove J, North J, Rankin SM, Kay AB, Robinson DS. Interleukin-5 regulates the isoform expression of its own receptor α-subunit. Blood 2000;95:1600-1607.
7. Sehmi R, Wardlaw AJ, Cromwell O, Kurihara K, Wahmann P, Kay AB. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood 1992;79:2952-2959.
8. Walsh GM, Hartnell A, Wardlaw AJ, Kurihara K, Sanderson CJ, Kay AB. IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner. Immunology 1990;71:258-265.
9. Rothenbeirg ME, Petersen J, Stevens RL, Silberstein DS, McKenzie DT, Austen KF, Owen WF. IL-5 dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity and sustained anti-body-dependent cytotoxicity. J Immunol 1989;143:2311-2316.
10. Hamid Q, Azzawi M, Ying S, Moqbel R, Wardlaw AJ, Corrigan CJ, Bradley B, Durham SR, Collins JV, Jeffrey PK, et al. Expression of mRNA for IL-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991;87:1541-1546.
11. Humbert M, Corrigan CJ, Durham SR, Kimmit P, Till SJ, Kay AB. Relationship between bronchial mucosal IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med 1997;156:704-708.
12. Robinson DS, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR. Activation of CD4+ T cells, increased Th2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in atopic asthmatics. J Allergy Clin Immunol 1993;92:313-324.
13. Robinson DS, Hamid Q, Ying S, Bentley AM, Assoufi B, North J, Meng Q, Durham SR, Kay AB. Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell IL-4, IL-5 and interferon-gamma cytokine gene expression. Am Rev Respir Dis 1993;148:401-406.
14. Mauser PJ, Pitman AM, Fenandez X, Foran SK, Adams GK, Kreutner W, Egan RW, Chapman RW. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med 1995;152:467-472.
15. Leckie M, Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Dukanovic R, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144-2148.
16. Leiferman KM, Ackerman SJ, Sampson HA, Haughen HS, Venecie PY, Gleich GJ. Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis: Comparison with onchocerciasis. N Engl J Med 1985;313:282-285.
17. Zeibecoglou K, Ying S, Yamada T, North J, Burman J, Bungre J, Meng Q, Kay AB, Robinson DS. Increased mature and immature CCR3 messenger RNA+ eosinophils in bone marrow from patients with atopic asthma compared with atopic and nonatopic control subjects. J Allergy Clin Immunol 1999;103:99-106.
18. Juniper E, Cockcroft D, Hargreave F. Histamine and Methacholine Inhalation Tests: Tidal Breathing Method: Laboratory Procedure and Standardisation. Lund, Sweden: AB Draco; 1991.
19. O'Byrne P, Inman M, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol 2001;108:503-508.
20. Kips J, O'Connor B, Langley S, Woodcock A, Kerstjens HAM, Postma DS, Danzig M, Cuss F, Pauwells RA. Results of a phase I trial with SCH55700, a humanised anti-IL-5 antibody in severe persistent asthma [abstract]. Am J Respir Crit Care Med 2000;161:A505.
21. Bentley A, Hamid Q, Robinson D, Scotman E, Meng Q, Assoufi B, Kay AB, Durham SR. Prednisolone treatment in asthma: Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5 and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 1996;153:551-556.
22. Hart T, Cook R, Zia-Amirhosseini P, Minthorn E, Sellers T, Maleeff B, Eustis S, Schwartz L, Tsui P, Appelbaum E, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanised monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001;108:250-257.
23. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB. Predominant TH-2 like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
24. MacFarlane AJ, Kon OM, Smith SJ, Zeibecoglou K, Khan LN, Barata LT, McEuen AR, Buckley MG, Walls AF, Meng Q, et al. Basophils, eosinophils, and mast cells in atopic and nonatopic asthma and in latephase allergic reactions in the lung and skin. J Allergy Clin Immunol 2000;105:99-107.
25. Wedemeyer J, Tsai M, Galli SJ. Roles of mast cells and basophils in innate and acquired immunity. Curr Opin Immunol 2000;12:624-631.
26. Denburg JA, Silver JE, Abrams JS, Interleukin-5 is a human basophilopoietin: Induction of histamine content and basophilic differentiation of HL-60 cells and of peripheral blood basophil-eosinophil progenitors. Blood 1991;77:1462-1468.
27. Bischoff SC, Brunner T, De Weck AL, Dahinden CA. Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists. J Exp Med 1990;172:1577-1582.
28. Yamada T, Sun Q, Zeibecoglou K, Bungre J, North J, Kay AB, Lopez AF, Robinson DS. IL-3, IL-5, granulocyte-macrophage colony-stimulating factor receptor alpha-subunit, and common beta-subunit expression by peripheral leukocytes and blood dendritic cells. J Allergy Clin Immunol 1998;101:677-682.